Ionis Pharmaceuticals Receives FDA Approval for TRYNGOLZA™

Ionis Pharmaceuticals (NASDAQ:IONS) saw a 6% increase in pre-open trading on Friday following the U.S. Food and Drug Administration (FDA) approval of TRYNGOLZA™ (olezarsen) for treating familial chylomicronemia syndrome (FCS), a rare and life-threatening disease. This approval is a significant milestone for the company, marking TRYNGOLZA as the first approved treatment for FCS in the U.S. Ionis anticipates this launch will be the first of four in the next three years.

TRYNGOLZA is intended for use alongside a low-fat diet and has demonstrated the ability to significantly reduce triglyceride levels, thereby lowering the risk of acute pancreatitis events in adults. The approval is based on positive results from the Phase 3 Balance clinical trial, which showed a statistically significant reduction in triglyceride levels along with a clinically meaningful decrease in acute pancreatitis events. The self-administered treatment is delivered via an auto-injector once a month and has a favorable safety profile.

CEO Brett P. Monia, Ph.D., described the FDA approval as a transformative moment for FCS patients and their families, emphasizing the treatment's potential to alter the disease's trajectory. This approval marks Ionis’s progression into a fully integrated commercial-stage biotechnology company, backed by a robust pipeline of prospective medicines.

The FDA's decision was heavily influenced by the outcomes of the Phase 3 Balance trial, previously published in The New England Journal of Medicine. Dr. Alan Brown, the trial's investigator, expressed his excitement at having an effective prescription option for FCS patients.

FCS is characterized by extremely high triglyceride levels and heightened risk for acute pancreatitis, which can be fatal. It's estimated that FCS affects around 3,000 individuals in the U.S., with many cases remaining undiagnosed. TRYNGOLZA is expected to be available in the U.S. by the end of the year, and Ionis plans to provide support services to facilitate patient access to the treatment.

TD Cowen analyst Yaron Werber echoed the company's excitement, stating, "Today's FDA approval of Tryngolza marks a key step forward in Ionis's commercial evolution as the company's first approval of a wholly-owned, independent product. Tryngolza is now the first and only approved therapy for FCS with a label that we believe is near best case."

The FDA approval includes Priority Review and previously granted Fast Track, Orphan Drug, and Breakthrough Therapy designations. Additionally, olezarsen is under review in the European Union, with plans for regulatory filings in other countries. Ionis is also evaluating olezarsen in three Phase 3 clinical trials aimed at treating severe hypertriglyceridemia (sHTG).

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.